Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ; Australasian Leukaemia Lymphoma Group (ALLG).

Haematologica. 2017 Feb;102(2):356-363. doi: 10.3324/haematol.2016.154039. Epub 2016 Nov 10.

2.
3.

FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome.

Han EJ, O JH, Yoon H, Jung SE, Park G, Choi BO, Cho SG.

Medicine (Baltimore). 2016 Sep;95(39):e4983. doi: 10.1097/MD.0000000000004983.

4.

High-frequency ultrasound analysis of post-mitotic arrest cell death.

Pasternak MM, Wirtzfeld LA, Kolios MC, Czarnota GJ.

Oncoscience. 2016 Apr 15;3(3-4):109-21. doi: 10.18632/oncoscience.301. eCollection 2016.

5.

FDG PET/CT Response Assessment Criteria for Patients with Hodgkin's and Non-Hodgkin's Lymphoma at End of Therapy: A Multiparametric Approach.

Metser U, Mohan R, Beckley V, Moshonov H, Hodgson D, Murphy G.

Nucl Med Mol Imaging. 2016 Mar;50(1):46-53. doi: 10.1007/s13139-015-0368-7. Epub 2015 Sep 29.

6.

Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma.

Yang DH, Jung SH, Ahn JS, Kim YK, Min JJ, Bom HS, Lee JJ, Kim HJ.

Chonnam Med J. 2015 Dec;51(3):109-14. doi: 10.4068/cmj.2015.51.3.109. Epub 2015 Dec 11. Review.

7.

Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.

Schöder H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, Moskowitz A, Noy A, Palomba L, Portlock C, Straus D, Grewal R, Migliacci JC, Larson SM, Moskowitz CH.

J Nucl Med. 2016 May;57(5):728-34. doi: 10.2967/jnumed.115.166769. Epub 2015 Dec 30.

8.

Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis.

Zhu D, Xu XL, Fang C, Ji M, Wu J, Wu CP, Jiang JT.

Int J Clin Exp Med. 2015 Sep 15;8(9):15340-50. eCollection 2015.

9.

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.

Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, Takahashi K, Glover C, Keane C, Kihira S, Visser B, Callahan J, Kong KA, Faham M, Corbelli KS, Miklos D, Advani RH, Levy R, Hicks RJ, Hertzberg M, Ohgami RS, Gandhi MK, Diehn M, Alizadeh AA.

Blood. 2015 Jun 11;125(24):3679-87. doi: 10.1182/blood-2015-03-635169. Epub 2015 Apr 17.

10.

Predictive value of interim PET/CT in DLBCL treated with R-CHOP: meta-analysis.

Sun N, Zhao J, Qiao W, Wang T.

Biomed Res Int. 2015;2015:648572. doi: 10.1155/2015/648572. Epub 2015 Feb 1. Review.

11.

The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy.

Coughlan M, Elstrom R.

Cancer Imaging. 2014 Nov 29;14:34. doi: 10.1186/s40644-014-0034-9. Review.

12.
13.

State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".

Kostakoglu L, Cheson BD.

Front Oncol. 2013 Sep 4;3:212. doi: 10.3389/fonc.2013.00212. Review.

14.

Prognostic value of interim (18)F-FDG PET/CT in diffuse large B-cell lymphoma.

Ying Z, Wang X, Song Y, Zheng W, Wang X, Xie Y, Lin N, Tu M, Ping L, Liu W, Deng L, Zhang C, Yang Z, Zhu J.

Chin J Cancer Res. 2013 Feb;25(1):95-101. doi: 10.3978/j.issn.1000-9604.2013.01.08.

15.

FDG-PET/CT based response-adapted treatment.

de Geus-Oei LF, Vriens D, Arens AI, Hutchings M, Oyen WJ.

Cancer Imaging. 2012 Sep 28;12:324-35. Review.

16.

The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma.

Hosein PJ, Lossos IS.

European J Clin Med Oncol. 2010 Feb;2(1):131-138.

17.

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.

Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, Perez DG, Soori GS, Link BK, Habermann TM, Witzig TE.

Blood. 2011 Oct 13;118(15):4053-61. doi: 10.1182/blood-2011-02-336990. Epub 2011 Jun 14.

18.

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.

Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL.

J Nucl Med. 2011 Mar;52(3):386-92. doi: 10.2967/jnumed.110.082586. Epub 2011 Feb 14.

19.

Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.

Terasawa T, Dahabreh IJ, Nihashi T.

Oncologist. 2010;15(7):750-9. doi: 10.1634/theoncologist.2010-0054. Epub 2010 Jun 29. Review.

20.

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD.

J Clin Oncol. 2010 Apr 10;28(11):1896-903. doi: 10.1200/JCO.2009.26.5942. Epub 2010 Mar 8.

Supplemental Content

Support Center